Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01406418 · ClinicalTrials.gov registry record · Phase 1
Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus
A Phase 1 study, sponsored by Crucell Holland.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01406418: Completed Phase 1 study, sponsored by Crucell Holland.
NCT01406418 is a Phase 1 study that has completed, run by Crucell Holland. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01406418, a Phase 1 study, has completed, sponsored by Crucell Holland.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to assess in healthy subjects the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses of CR6261, a monoclonal antibody against influenza A viruses.
Interventions
- BIOLOGICAL CR6261 2 mg/kg
- BIOLOGICAL CR6261 5 mg/kg
- BIOLOGICAL CR6261 15 mg/kg
- BIOLOGICAL CR6261 30 mg/kg
- BIOLOGICAL CR6261 50 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01406418
The ClinicalTrials.gov registry entry for NCT01406418 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crucell Holland, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CR6261 2 mg/kg is the first listed.
NCT01406418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01406418 about?
NCT01406418 is a clinical study titled "Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus". The purpose of this study is to assess in healthy subjects the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses of CR6261, a monoclonal antibody against influenza A viruses.
What is the current status of trial NCT01406418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2013-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01406418?
The interventions under investigation include: CR6261 2 mg/kg (BIOLOGICAL), CR6261 5 mg/kg (BIOLOGICAL), CR6261 15 mg/kg (BIOLOGICAL), CR6261 30 mg/kg (BIOLOGICAL), CR6261 50 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT01406418?
This trial is sponsored by Crucell Holland, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.